Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250 μg/Salmeterol 50 μg

Pulmonary Pharmacology and Therapeutics

Volumn 22, Issue 6, 2009, Pages 516-521

  Gelb, Arthur F ^a,b   Taylor, Colleen Flynn ^d   Simmons, Michael ^b   Shinar, Chris ^c  

^a Lakewood Regional Medical Center   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Orange Coast Memorial Medical Center   (United States)

^d NONE

Author keywords

Asthma; Cysteinyl leukotriene inhibitor; Exhaled nitric oxide; Salmeterol fluticasone; Zileuton

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL; NITRIC OXIDE; SALBUTAMOL; ZILEUTON;

ADD ON THERAPY; ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG WITHDRAWAL; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; GAS EXCHANGE; HEADACHE; HUMAN; LUNG FUNCTION; MALE; NAUSEA; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE BLIND PROCEDURE; SPIROMETRY;

ADULT; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASTHMA; DRUG THERAPY, COMBINATION; EOSINOPHILS; FEMALE; HUMANS; HYDROXYUREA; JUNIPERUS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NITRIC OXIDE; PROSPECTIVE STUDIES; PULMONARY ALVEOLI; RESPIRATORY FUNCTION TESTS; RESPIRATORY SYSTEM; SPIROMETRY;

EID: 71249127972     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2009.05.003     Document Type: Article

References (55)

1. National Asthmatic Education and Prevention Program. Guidelines for the Diagnosis and Management of asthma: expert panel report 3 (2007), National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD. Publication no. 07-4051. Accessed at: www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm
2. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention (2007), Paul O'Byrne Chair GINA Executive Committee. Accessed at: www.ginasthma.org
3. Asthma Guidelines. British Thoracic Society and Scottish Intercollegiate Guidelines Network. Accessed at: (2008). www.brit-thoracic.org.uk
4. Lemiere C., Bai T., Balter M., Bayliff C., Becker A., Boulet L.P., et al., on behalf of the Canadian Adult Asthma Consensus Group of Canadian Thoracic Society. Adult asthma consensus guidelines update 2003. Can Respir J 11 Suppl. A (2004) 9A-18A. Accessed at: www.lung.ca/cts
5. Kharitonov S.A., Gonio F., Kelly C., Meah S., and Barnes P.J. Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children. Eur Respir J 21 (2003) 433-438
6. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 171 (2005) 912-930
7. Tsoukias N.M., and George S.C. A two-compartment model of pulmonary nitric oxide exchange dynamics. J Appl Physiol 85 (1998) 653-666
8. Tsoukias N.M., Shin H.W., Wilson A.F., and George SC. A single-breath technique with variable flow rate to characterize nitric oxide exchange dynamics in the lungs. J Appl Physiol 91 (2001) 477-487
9. Gelb A.F., Flynn Taylor C., Nussbaum E., Gutierrez C., Schein A Shinar C.M., et al. Alveolar and airway sites of nitric oxide inflammation in treated asthma. Am J Respir Crit Care Med 170 (2004) 737-741
10. Berry M., Hargadon B., Morgan A., Shelley M., Richter J., Shaw D., et al. Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. Eur Respir J 25 (2005) 986-991
11. van Veen I.H., Sterk P.J., Schot R., Gauw S.A., Rabe K.F., and Bel E.H. Alveolar nitric oxide versus measures of peripheral airway dysfunction in severe asthma. Eur Respir J 27 (2006) 951-956
12. Lehtimaki L., Kankaanranta H., Saarelainen S., Turjanmaa V., and Moilanen E. Inhaled fluticasone decreases bronchial but not alveolar nitric oxide output in asthma. Eur Respir J 18 (2001) 635-639
13. Silkoff P.E., Lent A.M., Busacker A.A., Katial R.K., Balzar S., Strand M., et al. Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma. J Allergy Clin Immunol 116 (2005) 1249-1255
14. Lim S., Jatakanon A., Meah S., Gates T., Chung K.F., and Barnes P.J. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in mild to moderately severe asthma. Thorax 55 (2000) 184-188
15. Hamid Q., Springall D.R., Riveros-Moreno V., Chanez P., Howarth P., Redington A., et al. Induction of nitric oxide synthase in asthma. Lancet 342 (1993) 1510-1513
16. Ng D., Salvro F., and Hicks G. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2 (2004) CD002814
17. Green R.H., Brighting C.E., McKenna S., Hargadon B., Parker D., Bradding P., et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360 (2002) 1715-1721
18. Covar R.A., Szefler S.J., Martin R.J., Sundstrom D.A., Silkoff P.E., Murphy J., et al. Relation between exhaled nitric oxide and measures of disease activity among children with mild-to-moderate asthma. J Pediatr 142 (2003) 469-475
19. van Rensen E.L., Straathof K.C., Vaselic-Charvat M.A., Zwinderman A.H., Bel E.H., and Sterk P.J. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. Thorax 54 (1999) 403-408
20. Smith A.D., Cowan J.D., Brassett K.P., Herbison G.P., and Taylor D.R. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 352 (2005) 2163-2173
21. Silkoff P.E., McClean P., Spino M., Erlich L., Slutsky A.S., and Zamel N. Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone diproprionate therapy in asthma patients. Chest 119 (2001) 1322-1328
22. Kharitonov S.A., Donnelly L.E., Montuschi P., Corradi M., Collins J.V., and Barnes P.J. Dose-dependent onset onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma. Thorax 57 (2002) 889-896
23. Gelb A.F., Taylor C.F., Shinar C.M., Gutierrez C.A., and Zamel N. Effect of fluticasone 250 μg/salmeterol 50 μg and montelukast on exhaled nitric oxide in asthmatic patients. Can Respir J 15 (2008) 193-198
24. Nelson H., Kemp J., Berger W., Corren J., Casale T., Dube L., et al. Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma:a 3-month randomized controlled study. Ann Allergy Asthma Immunol 99 (2007) 178-184
25. Liu M.C., Dube L.M., and Lancaster J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. J Allergy Clin Immunol 111 (1996) 859-871
26. Israel E., Cohn J., Dube L., and Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: a randomized controlled trial. JAMA 111 (1996) 931-936
27. O'Conner B.J., Lofdahl C.G., Balter M., Szczeklik A., Boulet L.P., and Cairns C.B. Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma. Respir Med 101 (2007) 1088-1096
28. Lazarus S.C., Lee T., Kemp J.P., Wenzel S., Dube L., Ochs R., et al. Safety and clinical efficacy of Zileuton in patients with chronic asthma. Am J Man Care 4 (1998) 841-848
29. Gelb A.F., Hogg J.C., Muller N.L., Schein M.J., Kuei J., Tashkin D.P., et al. Contribution of emphysema and small airways in COPD. Chest 109 (1996) 353-359
30. George S.C., Hogman M., Permutt S., and Silkoff PE. Modeling pulmonary nitric oxide exchange. J Appl Physiol 96 (2004) 831-839
31. Silkoff P.E., McClean P.A., Slutsky A.S., Furlott H.G., Hoffstein V., Wakita S., et al. Marked flow-dependence of exhaled nitric oxide using a new technique to exclude nasal nitric oxide. Am J Respir Crit Care Med 155 (1997) 260-267
32. Condorelli P., Shin H.W., Aledia A.S., Silkoff P.E., and George S.C. A simple technique to characterize proximal and peripheral nitric oxide gas exchange using constant flow exhalation and an axial diffusion model. J Appl Physiol 102 (2007) 417-425
33. Gelb A.F., Flynn Taylor C., Shinar C.M., Gutierrez C.M., and Zamel N. Role of spirometry and exhaled nitric oxide to predict exacerbations in treated asthmatics. Chest 129 (2006) 1492-1499
34. Juniper E.F., Guyatt G.H., Cox F.M., Ferrie P.J., and King D.R. Development and validation of the mini asthma quality of life questionnaire. Eur Respir J 14 (1999) 32-38
35. Currie G.P., Lee D.K., Haggart K., Bates C.E., and Lipworth B.J. Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am J Respir Crit Care Med 167 (2003) 1232-1238
36. Ghiro L., Zanconato S., Rampon O., Piovan V., Pasquale M.F., and Baraldi E. Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children. Eur Respir J 20 (2002) 630-634
37. Laviolette M., Malmstrom K., Lu S., Chervinsky P., Pujet J.C., Peszek I., et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Monrelukast/Beclomethasone Additivity Group. Am J Resp Crit Care Med 160 (1999) 1862-1869
38. Szefler S.J., Phillips B.R., Martinez F.D., Chinchilli V.M., Lemanske R.F., Strunk R.C., et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 115 (2005) 233-242
39. Ducharme F.M., Schwartz Z., Hicks G., and Kakuma R. Addition of anti-leukotriene agents to inhaled corticosteroids in chronic asthma. Cochrane Database Syst Rev 2 (2004) CD003113
40. Bjermer L., Bisgaard H., Bousquet J., Fabbri L.M., Greening A.P., Haahtela T., et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 327 (2003) 891-897
41. Ilowite J., Webb R., Friedman B., Kerwin E., Bird S.R., Hustad C.M., et al. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind multicenter study. Ann Allergy Asthma Immunol 92 (2004) 641-648
42. Ducharme F.M., Lasserson T.J., and Cates C.J. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic persistent asthma. Cochrane Database Syst Rev 4 (2006) CD3137
43. Emst P., McIvor A., Ducharme F.M., Boulet L.P., Fitzgerald M., Chapman K., et al. Safety and effectiveness of long-acting inhaled beta-agonist bronchodilators when taken with inhaled corticosteroids. Ann Intern med 145 (2006) 692-694
44. Deykin A., Wechsler M.E., Boushey H.A., Chinchilli V.M., Kunselman S.J., Craig T.J., et al. Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma. Am J Respir Crit Care Med 175 (2007) 228-234
45. Fritscher L.G., Rodrigues M.T., Zamel N., and Chapman K.R. The effect of montelukast on exhaled nitric oxide of alveolar and bronchial origin in inhaled corticosteroid-treated asthma. Respir Med 103 (2009) 296-300
46. Mahut B., Delacourt C., Zerah-Lancner F., DeBlic J., Harf A., and Delclaux C. Increase in alveolar nitric oxide in the presence of symptoms in childhood asthma. Chest 125 (2004) 1012-1018
47. Hogman M., Holmkvist T., Wegener T., Emtner M., Anderson M., Hedenstrom H., et al. Extended nitric oxide analysis applied to patients with COPD, allergic asthma, and allergic rhinitis. Respir Med 96 (2002) 24-30
48. Shin H.W., Rose-Gottron C.M., Cooper D.M., Newcomb R.L., and George S.C. Airway diffusing capacity of nitric oxide and steroid therapy in asthma. J Appl Physiol 96 (2004) 65-75
49. Peters-Golden M., and Henderson Jr. W.R. Leukotrienes. N Engl J Med 357 (2007) 1841-1854
50. Ogawa Y., and Calhoun W.J. The role of leukotrienes in airway inflammation. J Allergy Clin Immunol 118 (2006) 789-798
51. Miranda C., Busacker A., Balzar S., Trudeau J., and Wenzel S.E. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 113 (2004) 101-108
52. Kraft M., Djukanovic R., Wilson S., Holgate S.T., and Martin R.J. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 154 (1996) 1505-1510
53. Mauad T., Silva L.F., Santos M.A., Grinberg L., Bernardi F.D., Martins M.A., et al. Abnormal alveolar attachments with decreased elastic fiber content in distal lung in fatal asthma. Am J Respir Crit Care Med 170 (2004) 857-862
54. Gelb A.F., and Zamel N. Unsuspected pseudophysiologic emphysema in chronic persistent asthma. Am J Respir Crit Care Med 162 (2000) 1778-1782
55. Gelb A.F., Licuanan J., Shinar C.M., and Zamel N. Unsuspected loss of lung elastic recoil in chronic persistent asthma. Chest 121 (2002) 715-721